Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AP-SA02
- Development stage
- Phase 2
- Lead developer
- Armata Pharmaceuticals
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
AP-SA02 is Armata Pharmaceuticals' investigational, intravenously administered fixed multi-bacteriophage cocktail for use as an adjunct to best available antibiotic therapy in complicated *Staphylococcus aureus* bacteremia, including infections caused by methicillin-sensitive and methicillin-resistant strains. Its lytic phages selectively infect *S. aureus*, replicate within susceptible bacterial cells, and lyse them; the product is intended to provide activity distinct from and potentially synergistic with antibiotics, including against established biofilms. The completed Phase 1b/2a diSArm study supported advancement planning toward a pivotal Phase 3 superiority study, which Armata continued to describe as anticipated to initiate in the second half of 2026. ([armatapharma.com](https://www.armatapharma.com/pipeline/ap-sa02/))
- Other names
- APSA02APSA-02APSA 02
Beyond the preview
Go deeper on AP-SA02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AP-SA02.